Market Research Future has recently declared the expansion of a new research study to its thorough collection of research reports “Worldwide Macrolide Antibiotics Market Research Report 2018”.
Macrolide Antibiotics Market – Scenario
Macrolides such as azithromycin, clarithromycin, and erythromycin are a class of antibiotics that inhibit protein synthesis. It acts as a bacteriostatic agent against many strains of corynebacteria, listeria, moxicella, streptococci, Neisseria meningitides, Staphylococci, Clostridia, and Haemophilus sp.
It is used for the treatment of bacterial infections, such as nose, ear, and throat infections, chest infections, skin infections as well as mouth and dental infections. They are also used as an alternative to penicillin.
Try Premium Sample Copy @ https://www.marketresearchfuture.com/sample_request/4342
Macrolide antibiotics Market -Major Key Players
- Merck Sharp & Dohme Corp (U.S.)
- Pfizer Inc. (U.S.)
- Neo Química (Brazil)
- Macrolide Pharmaceuticals (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Fresenius Kabi USA (U.S.)
- Sandoz International GmbH (Germany)
- Gland Pharma Limited (India)
- Mylan N.V. (U.S.)
- WOCKHARDT (U.S.)
Macrolide antibiotics Market -Regional Analysis
The global macrolide antibiotics market consists of four regions: the Americas, Europe, Asia Pacific, and the Middle East & Africa. The Americas dominates the global macrolide antibiotics market. It comprises of two regions namely North America and South America.
In Europe, increasing use of azithromycin, and erythromycin has led to the rise in the demand for the macrolide antibiotics. France accounts for the largest market share followed by Germany owing to the increasing incidence of skin diseases.
Expansion of healthcare system in developing countries in Asia Pacific also favors the market growth. The Middle East & Africa is expected to witness a steady growth in this market.
Macrolide antibiotics Market- Growth and Analysis
The global macrolide antibiotics market is expected to show a sharp growth over the forecast period owing to an increasing demand for macrolide across the globe. Rising prevalence of bacterial skin infections and rising number of dermatology clinics also favor the market growth.
According to a study published in the Journal of the American College of Cardiology, macrolide antibiotics may increase the risk of sudden cardiac death, ventricular tachyarrhythmias, and cardiovascular death in patients, which may hinder the growth of the market over the assessment period.
The global macrolide antibiotics market is expected to grow at a CAGR of 12.5% during the forecast period 2017-2023.
Macrolide antibiotics Market -Segmentation
The global macrolide antibiotics market is segmented on the basis of drugs, which includes azithromycin, clarithromycin, erythromycin, fidaxomicin, and telithromycin. On the basis of route of administration, the market is segmented into oral, parenteral.
On the basis of indication, the market is segmented into infection due to mycoplasma pneumoniae, legionella sp, or bordetella pertussis, symptomatic cat-scratch disease, bacillary angiomatosis, peliosis hepatis in patients with AIDS, cerebral toxoplasmosis, uncomplicated skin infections, and others.
On the basis of end user, the market is segmented into hospitals, dermatology clinics, pharmaceutical companies, and others.
Global Macrolide Antibiotics -Some Points from TOC
1 Report Prologue
2 Market Introduction
2.2 Scope of the Study
2.2.1 Research Objective
3 Research Methodology
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
For Specific Requirements, Ask Our Experts @ https://www.marketresearchfuture.com/enquiry/4342
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Phone: +1 646 845 9312